There are limited compelling pharmaceutical options to treat devastating neurological conditions including Alzheimer's Disease and Parkinson's Disease. Current approved medications primarily treat symptoms and have limited impact on cognition.

KeifeRx is building upon its extensive clinical experience at Georgetown University in neurodegenerative diseases to advance a second generation of orally delivered small molecules that improve blood-brain-barrier penetration by 30x-50x enhancing the clearance of toxic proteins while avoiding inflammation and brain bleeding that is a common side effect of existing treatments.

Completed Phase II clinical trial using one of our drugs at Georgetown University for the treatment of Lewy Body Dementia. The trial showed a 2.8 point improvement on a cognitive scale after 3 months equating to a 12-18 month delay in cognitive decline. This is 2x the improvement seen by existing approved drugs in 1/2 the treatment time.

Completed substantially all of the pre-clinical testing on 4 novel 2nd generation drugs showing best-in-class toxic protein reduction with no negative safety findings.